Literature DB >> 32720402

Adropin as a potential mediator of the metabolic system-autonomic nervous system-chronobiology axis: Implementing a personalized signature-based platform for chronotherapy.

Yotam Kolben1, Sarah Weksler-Zangen1, Yaron Ilan1.   

Abstract

Adropin is a peptide hormone, which plays a role in energy homeostasis and controls glucose and fatty acid metabolism. Its levels correlate with changes in carbohydrate-lipid metabolism, metabolic diseases, central nervous system function, endothelial function and cardiovascular disease. Both metabolic pathways and adropin are regulated by the circadian clocks. Here, we review the roles of the autonomic nervous system and circadian rhythms in regulating metabolic pathways and energy homeostasis. The beneficial effects of chronotherapy in various systems are discussed. We suggest a potential role for adropin as a mediator of the metabolic system-autonomic nervous system axis. We discuss the possibility of establishing an individualized adropin and circadian rhythm-based platform for implementing chronotherapy, and variability signatures for improving the efficacy of adropin-based therapies are discussed.
© 2020 World Obesity Federation.

Entities:  

Keywords:  adropin; autonomic nervous system; chronobiology; metabolic syndrome

Year:  2020        PMID: 32720402     DOI: 10.1111/obr.13108

Source DB:  PubMed          Journal:  Obes Rev        ISSN: 1467-7881            Impact factor:   9.213


  12 in total

1.  Microtubules as a potential platform for energy transfer in biological systems: a target for implementing individualized, dynamic variability patterns to improve organ function.

Authors:  Yaron Ilan
Journal:  Mol Cell Biochem       Date:  2022-07-13       Impact factor: 3.842

Review 2.  Why scientists, academic institutions, and investors fail in bringing more products to the bedside: the Active Compass model for overcoming the innovation paradox.

Authors:  Yaron Ilan
Journal:  J Transl Med       Date:  2021-02-04       Impact factor: 5.531

3.  Improving Global Healthcare and Reducing Costs Using Second-Generation Artificial Intelligence-Based Digital Pills: A Market Disruptor.

Authors:  Yaron Ilan
Journal:  Int J Environ Res Public Health       Date:  2021-01-19       Impact factor: 3.390

Review 4.  Digital Medical Cannabis as Market Differentiator: Second-Generation Artificial Intelligence Systems to Improve Response.

Authors:  Yaron Ilan
Journal:  Front Med (Lausanne)       Date:  2022-01-24

Review 5.  A Subject-Tailored Variability-Based Platform for Overcoming the Plateau Effect in Sports Training: A Narrative Review.

Authors:  Ram Gelman; Marc Berg; Yaron Ilan
Journal:  Int J Environ Res Public Health       Date:  2022-02-02       Impact factor: 3.390

Review 6.  Digital Analgesic Comprising a Second-Generation Digital Health System: Increasing Effectiveness by Optimizing the Dosing and Minimizing Side Effects.

Authors:  Henny Azmanov; Areej Bayatra; Yaron Ilan
Journal:  J Pain Res       Date:  2022-04-13       Impact factor: 2.832

7.  Hepatic adropin is regulated by estrogen and contributes to adverse metabolic phenotypes in ovariectomized mice.

Authors:  Joshua Stokar; Irina Gurt; Einav Cohen-Kfir; Oran Yakubovsky; Noa Hallak; Hadar Benyamini; Natan Lishinsky; Neta Offir; Joseph Tam; Rivka Dresner-Pollak
Journal:  Mol Metab       Date:  2022-03-29       Impact factor: 8.568

8.  Effect of Long-Term Continuous Light Exposure and Western Diet on Adropin Expression, Lipid Metabolism, and Energy Homeostasis in Rats.

Authors:  Mahmoud Mustafa Ali Abulmeaty; Ali Madi Almajwal; Khalid S Alnumair; Suhail Razak; Mai Mohammed Hasan; Amal Fawzy; Abdullah Ibrahim Farraj; Manal Abudawood; Ghadeer S Aljuraiban
Journal:  Biology (Basel)       Date:  2021-05-07

9.  Adropin Alleviates Myocardial Fibrosis in Diabetic Cardiomyopathy Rats: A Preliminary Study.

Authors:  Mao Liu; Jiao Ai; Zhuang Shuai; Kai Tang; Zongyu Li; Yin Huang
Journal:  Front Cardiovasc Med       Date:  2021-07-12

Review 10.  Establishing a second-generation artificial intelligence-based system for improving diagnosis, treatment, and monitoring of patients with rare diseases.

Authors:  Noa Hurvitz; Henny Azmanov; Asa Kesler; Yaron Ilan
Journal:  Eur J Hum Genet       Date:  2021-07-19       Impact factor: 5.351

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.